CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a morning shot fight cancer better?
Disease control Recruiting nowThis study is testing whether giving two immunotherapy drugs (ipilimumab and nivolumab) at specific times of day improves how well they work for advanced melanoma. Researchers want to see if receiving treatment in the morning, afternoon, or late afternoon leads to better survival…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Custom-Made vaccine trial launches for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing the safety of a personalized vaccine designed to train a patient's immune system to attack their specific cancer. It is for adults with advanced breast cancer, melanoma, or non-small cell lung cancer that has continued to grow despite standard tr…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Dual attack: fighting cancer while protecting a transplanted kidney
Disease control Recruiting nowThis study is testing a new treatment approach for people who have had a kidney transplant and now have advanced skin cancer that cannot be removed by surgery or has spread. The goal is to see if a combination of cancer immunotherapy drugs (nivolumab and ipilimumab) can be given …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug duo aims to outsmart tough cancers that resist standard treatment
Disease control Recruiting nowThis study is testing whether combining two drugs, cabozantinib and nivolumab, can help control advanced melanoma or head and neck cancer that has worsened despite standard immunotherapy. It will enroll about 150 adults whose cancer has progressed on prior treatment. A key goal i…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Donor immune cells target deadly brain tumors in new cancer trial
Disease control Recruiting nowThis early-stage trial is testing a new combination treatment for melanoma that has spread to the brain. Researchers are giving patients immune cells from a universal donor (called NK cells) along with a standard chemotherapy drug (temozolomide). The study aims to find the safest…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Kari Kendra • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New pill combo targets deadly melanoma in the brain
Disease control Recruiting nowThis study is testing if two oral drugs, binimetinib and encorafenib, can help control melanoma that has spread to the brain or spinal fluid. It is for adults whose melanoma has a specific genetic change called BRAF V600 and has progressed after prior treatment. The main goals ar…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Brain battle: two drug cocktails face off against deadly melanoma spread
Disease control Recruiting nowThis trial is testing which of two drug combinations works better for people with advanced melanoma that has spread to the brain. One group gets three drugs (encorafenib, binimetinib, nivolumab), while the other gets two drugs (ipilimumab, nivolumab). The main goal is to see whic…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New pill targets tough cancers in early safety trial
Disease control Recruiting nowThis is a first-in-human study to find a safe dose of a new oral drug called IACS-6274. It will be tested alone and in two different drug combinations in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the safety …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Custom-Made vaccine aims to train immune system to fight advanced cancers
Disease control Recruiting nowThis study is testing a new, personalized vaccine designed to target the unique proteins on a patient's own cancer cells. It is being given alongside an existing immunotherapy drug (pembrolizumab) to see if the combination is safe and can help control advanced solid tumors that h…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Cancer care comes home: mayo clinic tests At-Home immunotherapy shots
Disease control Recruiting nowThis study is testing whether giving a cancer immunotherapy treatment called nivolumab as an injection at home is a safe and practical alternative to receiving it at a clinic. It aims to see if home treatment reduces the burden of travel and improves quality of life for patients …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
Fat-Fueled fight: can a special diet boost cancer treatment?
Disease control Recruiting nowThis study is testing whether following a strict high-fat, low-carbohydrate (ketogenic) diet is safe and feasible for patients with advanced melanoma or kidney cancer who are receiving immunotherapy. Researchers want to see if changing the body's main fuel source from sugar to fa…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 04, 2026 15:29 UTC
-
Scientists seek clues in blood to unlock cancer treatment mystery
Knowledge-focused Recruiting nowThis study aims to understand why some patients with advanced cancers like melanoma and lung cancer respond well to a common immunotherapy (anti-PD-1), while others do not. Researchers will collect blood samples from 500 patients to measure specific markers in immune cells during…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:56 UTC
-
Could poop transplants ease cancer drug side effects?
Knowledge-focused Recruiting nowThis study aims to understand why some cancer patients develop severe diarrhea and colon inflammation (colitis) while taking powerful immunotherapy drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 patients with melanoma…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 05, 2026 14:00 UTC